Exact Sciences Announces Third-Quarter 2024 Financial Results: Revenue Growth and Regulatory Approvals

Details

The company reported Screening revenue of $545 million and Precision Oncology revenue of $164 million. Adjusted EBITDA increased by 500 basis points to 14%, and the company generated operating cash flow of $139 million and free cash flow of $113 million. Additionally, Exact Sciences received FDA approval for the Cologuard Plus test, its next-generation colorectal cancer screening test.

Items reported

Exhibits (1)

About Exact Sciences Corp

Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.